PlusTherapeuticsInc . (NASDAQ:PSTV) shares rose 7.4% on Monday . The company traded as high as $2.19 and last traded at $2.17, approximately 281,159 shares traded hands during mid-day trading. A decline of 0% from the average daily volume of 281,281 shares. The stock had previously closed at $2.02.
Separately, ValuEngine raised shares of PlusTherapeuticsInc . from a “hold” rating to a “buy” rating in a research note on Tuesday, September 24th.
The company has a debt-to-equity ratio of 4.28, a quick ratio of 1.54 and a current ratio of 1.54. The firm’s 50 day simple moving average is $2.36.
A hedge fund recently bought a new stake in PlusTherapeuticsInc . stock. Sabby Management LLC acquired a new position in PlusTherapeuticsInc . (NASDAQ:PSTV) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 113,600 shares of the company’s stock, valued at approximately $389,000. Sabby Management LLC owned 25.24% of PlusTherapeuticsInc . as of its most recent SEC filing. Institutional investors and hedge funds own 88.89% of the company’s stock.
About PlusTherapeuticsInc . (NASDAQ:PSTV)
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer.
Further Reading: Bollinger Bands
Receive News & Ratings for PlusTherapeuticsInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PlusTherapeuticsInc . and related companies with MarketBeat.com's FREE daily email newsletter.